Related Experiment Videos
Cytokines in inflammatory bowel disease
World Journal of Surgery
|April 2, 1998
Summary
Cytokines, crucial for intestinal immunity, are imbalanced in inflammatory bowel disease (IBD). Targeting these cytokines shows promise for IBD treatment, though further research is needed.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Cytokines are key regulators of the intestinal immune system, with both pro-inflammatory and anti-inflammatory roles.
- Elevated levels of pro- and anti-inflammatory cytokines are observed in inflammatory bowel disease (IBD).
- An imbalance in cytokine profiles, specifically the IL-1/IL-1ra ratio, is noted in inflamed tissues of IBD patients.
Purpose of the Study:
- To explore the role of cytokines in intestinal immunity and inflammation.
- To investigate the potential of cytokine modulation as a therapeutic strategy for IBD.
- To review the rationale and early clinical findings for cytokine-based IBD treatments.
Main Methods:
- Analysis of cytokine concentrations in IBD patients.
- Evaluation of cytokine inhibition and supplementation in animal models of colitis (DSS, TNBS, IL-10 knockout).
- Review of early clinical trials using anti-TNF alpha and anti-IL-10 therapies.
Main Results:
- Cytokine imbalances, particularly the IL-1/IL-1ra ratio, are associated with various forms of colitis.
- Modulating cytokine activity in animal models demonstrated reduced inflammation.
- Initial clinical trials with anti-TNF alpha and IL-10 showed encouraging outcomes for IBD.
Conclusions:
- Cytokine dysregulation is a significant factor in IBD pathogenesis.
- Targeting cytokines offers a potential therapeutic avenue for IBD.
- Further investigation is required to establish cytokine-based therapies as standard treatment for IBD.